 |
|
|
| |
HCV Reinfection Intervention in HCV/HIV MSM - Swiss Cohort
|
| |
| |
EACS: High incidence of HCV reinfection in HIV-positive MSM in the DAA era - (10/30/17)
EACS: High SVR 12 rates with grazoprevir/elbasvir ± ribavirin for 12-16 weeks guided by genotypic resistance testing among HIV/HCV coinfected MSM in the Swiss HCVree Trial (10/30/17)
EACS: Impact of Diabetes and Age on Kidneys During DAA Therapy for HCV/HIV - written by Mark Mascolini (10/30/17)
Evolution of renal function during treatment with direct antiviral agents (DAA-t) in HIV/HCV infected patients in ICONA/HepaIcona cohorts - (11/08/17)
Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review - (10/28/17)
⋅ 15⋅6 million (uncertainty interval [UI] 10⋅2-23⋅7 million) people inject drugs
⋅ Less than 1% of all PWID live in countries with high coverage of both NSP and OST.
⋅ HCV antibody prevalence from 50% (38-63) in east and southeast Asia to 65% (57-73) in eastern Europe Rapid scale-up of NSP and OST is urgently needed in regions where injecting drug use is an emerging issue, such as sub-Saharan Africa.....
⋅ Russia (with an estimated 1⋅9 million PWID [UI 1⋅0-3⋅1], 30% [18-43] of whom are estimated to be living with HIV, and 69% [60-78] with HCV antibodies)1 is the only country in the eastern European region that does not provide OST, and access to NSP is very limited.
⋅ The three regions with the largest populations of PWID-east and southeast Asia, eastern Europe, and North America-were all estimated to have poor coverage of NSP and OST. These are all regions where injecting drug use is well established. HIV prevalence in these regions is estimated to range from 9% (UI 7-11) in North America to 25% (16-34) in eastern Europe, and .......
⋅ HCV antibody prevalence from 50% (38-63) in east and southeast Asia to 65% (57-73) in eastern Europe
⋅ The three regions worldwide with the highest populations of people who inject drugs, East and South-East Asia, Eastern Europe and North America, all had poor provision of needle syringe programs and opioid substitution therapy.....
|
| |
|
|
|
|
|
